Oral Minoxidil Regulatory Status: US, EU, Canada, and UK Approvals Explained

At a glance

• US oral tablets / Prescription; approved only for severe hypertension [1]
• US hair loss / Not an approved oral indication [1]
• Loniten brand / NDA 018154 approved 10/18/1979; 2.5 mg and 10 mg listed discontinued [2]
• US topical 2% solution / Over the counter since the 1996 switch [3]
• US topical 5% solution / Labeled for regrowth on the top of the scalp [4]
• UK, EU, Canada / Not established by the US FDA records [1][2]
• Hair-loss trials / Off-label research, not an approval [1][5]

What Is the US Approval Status?

The FDA-approved oral minoxidil product is a prescription tablet for hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum doses of a diuretic plus two other antihypertensive drugs [1]. The label says use in milder hypertension is not recommended [1]. Loniten, the original brand, was approved as NDA 018154 on 10/18/1979; its 2.5 mg and 10 mg tablets are now listed as discontinued, with an FDA determination that the discontinuation was not for safety or effectiveness reasons [2]. The oral label states that use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication [1]. Low-dose oral minoxidil for hair loss is therefore off-label in the US [1].

Does Topical Minoxidil Change the Answer?

No. Topical minoxidil is a separate product line with its own record. FDA records list the Rogaine 2% topical solution as over the counter; the product was originally approved 08/17/1988 and the Rx-to-OTC switch was approved 02/09/1996 [3]. The men's 5% topical solution is labeled to regrow hair on the top of the scalp, vertex only, and the label says it is not intended for frontal baldness or a receding hairline [4]. Neither topical record changes the status of the oral tablet, which remains a prescription medicine for severe hypertension [1].

What About the UK, EU and Canada?

The FDA label and Drugs@FDA record are US records. They do not establish what the MHRA, European regulators or Health Canada have authorized for oral minoxidil [1][2]. Any named national approval, marketing status, tablet strength or reimbursement rule would have to come from that country's own product record.

Why a Hair-Loss Trial Is Not an Approval

A 2021 review of 17 studies with 634 patients concluded oral minoxidil appeared effective and well tolerated in healthy patients who had trouble with topical use, and called for larger randomized dose-comparison studies [5]. A 2021 retrospective study of 1,404 patients found hypertrichosis in 15.1% and systemic effects led to discontinuation in 29 patients (1.2%); it had no control group [6]. A 2025 international consensus statement addresses low-dose oral minoxidil as off-label prescribing for hair loss [7]. These clinical findings do not change the approved indication [1].

Frequently asked questions

›Is oral minoxidil FDA-approved for hair loss?

No. The oral tablet label says use to promote hair growth in any formulation is not an approved indication; oral minoxidil is approved only for severe hypertension [1].

›Is Loniten still marketed in the US?

Drugs@FDA lists Loniten 2.5 mg and 10 mg tablets as discontinued, with an FDA determination that the discontinuation was not for safety or effectiveness reasons [2].

›Does the OTC status of topical minoxidil apply to oral tablets?

No. FDA records list the 2% topical solution as over the counter, while the oral tablet is a prescription hypertension medicine [1][3].

›Are oral minoxidil approvals the same in the UK, EU and Canada?

The US FDA records do not establish those countries' decisions; each country's own product record would be needed [1][2].

›Do hair-loss trials make low-dose oral minoxidil approved?

No. A trial result does not change a product's approved indication; low-dose oral minoxidil for hair loss remains off-label in the US [1][7].

References

1. U.S. National Library of Medicine, DailyMed. Minoxidil tablets (oral) prescribing information. DailyMed - MINOXIDIL tablet
2. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
3. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
4. U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
5. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737-746. Oral minoxidil treatment for hair loss: A review of efficacy and safety
6. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones ÓM, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
7. Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, et al. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement. JAMA Dermatol. 2025;161(1):87-95. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement